OncoSec Medical Incorporated (NASDAQ:ONCS) is scheduled to release its earnings data before the market opens on Wednesday, October 11th. Analysts expect OncoSec Medical to post earnings of ($0.24) per share for the quarter.

Shares of OncoSec Medical Incorporated (NASDAQ ONCS) opened at 0.9774 on Wednesday. OncoSec Medical Incorporated has a 12 month low of $0.88 and a 12 month high of $2.08. The company’s market cap is $20.69 million. The stock’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.08.

Several research analysts have weighed in on ONCS shares. ValuEngine downgraded OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Monday. Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a report on Friday, September 1st. Dawson James reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th. Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a report on Monday, June 12th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $5.33.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/oncosec-medical-incorporated-oncs-set-to-announce-earnings-on-wednesday.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Earnings History for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.